Showing results (11-20 of 71) with videos related to

Sort By:
Pageof 8
Clinical Lymphoma, Myeloma & Leukemia|June 1, 2025
Clinical Outcomes for Multiple Myeloma Patients With Prior Exposure to a Combination of a Proteasome Inhibitor and an Immunomodulatory Agent in Alberta, CanadaVictor H Jimenez-Zepeda, Mariet Mathew Stephen, Henry Chan, et al.
Future Oncology (London, England)|November 18, 2025
Clinical outcomes and healthcare resource use in triple-class exposed patients with relapsed/refractory multiple myelomaVictor H Jimenez-Zepeda, Winson Y Cheung, Mariet Mathew Stephen, et al.
Annals of Hematology|January 12, 2017
Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myelomaVictor H Jimenez-Zepeda, Peter Duggan, Paola Neri, et al.
Leukemia & Lymphoma|November 22, 2017
Immunoparesis and polyclonal immunoglobulin recovery after auto-SCT for patients with multiple myeloma treated at a single institutionVictor H Jimenez-Zepeda, Peter Duggan, Paola Neri, et al.
Leukemia & Lymphoma|August 14, 2012
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myelomaVictor H Jimenez-Zepeda, Donna E Reece, Suzanne Trudel, et al.
Leukemia & Lymphoma|July 6, 2022
Real-world treatment patterns for patients with newly diagnosed multiple myeloma in Alberta, CanadaVictor H Jimenez-Zepeda, Guanmin Chen, Eileen Shaw, et al.
American Journal of Hematology|August 5, 2011
Cyclophosphamide and prednisone induction followed by cyclophosphamide mobilization effectively decreases the incidence of engraftment syndrome in patients with POEMS syndrome who undergo stem cell transplantationVictor H Jimenez-Zepeda, Suzanne Trudel, Donna E Reece, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 19, 2016
Revised International Staging System Applied to Real World Multiple Myeloma PatientsVictor H Jimenez-Zepeda, Peter Duggan, Paola Neri, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|June 7, 2021
Treatment response measurements and survival outcomes in a cohort of newly diagnosed AL amyloidosisVictor H Jimenez-Zepeda, Holly Lee, Sylvia McCulloch, et al.
Annals of Hematology|July 21, 2021
N-Terminal pro-brain natriuretic peptide (NTproBNP) in patients with symptomatic multiple myeloma: report from a single institutionVictor H Jimenez-Zepeda, Holly Lee, Jason Tay, et al.
Pageof 8